Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma

Por Primack, Aron, Vogel, Charles L., Barker, Lewellys F.
Publicado em 1973

Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

Por Montero, Alberto J., Escobar, Mauricio, Lopes, Gilberto, Glück, Stefan, Vogel, Charles
Publicado em 2012

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Por Vogel, Charles, Chan, Arlene, Gril, Brunilde, Kim, Sung-Bae, Kurebayashi, Junichi, Liu, Li, Lu, Yen-Shen, Moon, Hanlim
Publicado em 2010

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

Por Vahdat, Linda T., Garcia, Agustin A., Vogel, Charles, Pellegrino, Christine, Lindquist, Deborah L., Iannotti, Nicholas, Gopalakrishna, Prashanth, Sparano, Joseph A.
Publicado em 2013

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Por Zeichner, Simon B, Ambros, Tadeu, Zaravinos, John, Montero, Alberto J, Mahtani, Reshma L, Ahn, Eugene R, Mani, Aruna, Markward, Nathan J, Vogel, Charles L
Publicado no Breast Cancer (Auckl) (2015)

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

Por Hugh, Judith, Hanson, John, Cheang, Maggie Chon U., Nielsen, Torsten O., Perou, Charles M., Dumontet, Charles, Reed, John, Krajewska, Maryla, Treilleux, Isabelle, Rupin, Matthieu, Magherini, Emmanuelle, Mackey, John, Martin, Miguel, Vogel, Charles
Publicado em 2009

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Por Kaufman, Peter A, Bloom, Kenneth J, Burris, Howard, Gralow, Julie R, Mayer, Musa, Pegram, Mark, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chau, Miu, Lalla, Deepa, Yoo, Bongin, Brammer, Melissa G, Vogel, Charles L
Publicado no Cancer (2014)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Por Girish, Sandhya, Gupta, Manish, Wang, Bei, Lu, Dan, Krop, Ian E., Vogel, Charles L., Burris III, Howard A., LoRusso, Patricia M., Yi, Joo-Hee, Saad, Ola, Tong, Barbara, Chu, Yu-Waye, Holden, Scott, Joshi, Amita
Publicado em 2012

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Por Pajares, Bella, Pollán, Marina, Martín, Miguel, Mackey, John R, Lluch, Ana, Gavila, Joaquín, Vogel, Charles, Ruiz-Borrego, Manuel, Calvo, Lourdes, Pienkowski, Tadeusz, Rodríguez-Lescure, Álvaro, Seguí, Miguel Angel, Tredan, Olivier, Antón, Antonio, Ramos, Manuel, Cámara, María del Carmen, Rodríguez-Martín, César, Carrasco, Eva, Alba, Emilio
Publicado em 2013